Warner-Lambert Company

Pfizer Corporation

Merck Sharp + Dohme Corp.

Clare Octavia Kneen

David Christopher Horwell

Justin Stephen Bryans

David Juergen Wustrow

Giles Stuart Ratcliffe

Thomas Capiris

Andrew I Morrell

Raymond Baker

Christopher John Swain

Johannes Hartenstein

Thomas R Belliotti

Andrew John Thorpe

John Saunders

4(3)substituted-4(3)-aminomethyl-(thio)pyran or piperidine derivatives (&equals;gabapentin analogues), their preparation and their use in the treatment of neurological disorders

Novel gamma aminobutyric acids of formula (I) are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammation, and gastrointestinal damage. Processes for the preparation and intermediates useful in the preparation are also disclosed.

Amines as pharmaceutical agents

Novel amines of formulas (1), (1C), (1F), (1G) and (1H) or a pharmaceutical acceptable salt thereof wherein n is an integer of from 0 to 2; m is an integer of from 0 to 3; R is sulfonamide, amide, phosphonic acid, heterocycle, sulfonic acid, or hydroxamic acid; A&prime; is a bridged ring selected from (1), (2), (3), (4), (5) wherein is the point of attachment; Z to Z are each independently selected from hydrogen and methyl; o is an integer of from 1 to 4; and p is an integer of from 0 to 2. In formula (1) above R cannot be sulfonic acid when m is 2 and n is 1 are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, especially irritable bowel syndrome.

1-substituted-1-aminomethyl-cycloalkane derivatives (&equals;gabapentin analogues), their preparation and their use in the treatment of neurological disorders

Substituted gamma aminobutyric acids as pharmaceutical agents

Substituted cyclic amino acids as pharmaceutical agents

Bridged cyclic amino acids as pharmaceutical agents

Cyclic amino acids as pharmaceutical agents

The present invention provides a compound of formula I or a salt or prodrug thereof: ##STR1## wherein the dotted line represents an optional chemical bond in one of the two possible positions; A represents a group of formula II: ##STR2## in which R.sup.1 represents hydrogen, hydroxy, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 alkoxy, benzyloxy, hydroxy (C.sub.1-6)alkyl, halogen, amino, cyano, nitro, --CONR.sup.6 R.sup.7 or --SO.sub.2 NR.sup.6 R.sup.7, in which R.sup.6 and R.sup.7 independently represent hydrogen, halogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl;

Spirocyclic compounds incorporating five-membered rings with two

Growing community of inventors

Essex, United Kingdom

Clare Octavia Kneen